
Keywords: ADCs; antibody-drug-conjugates; ALL; acute lymphocytic leukemia; AML; acute myeloid leukemia; B-NHL; B-cell non-Hodgkin's lymphoma; ccRCC; clear cell renal cell carcinoma; DLBCL; diffuse large B-cell lymphoma; DAR; drug to antibody ratio; ECM; extra cellu